Various
Pipeline by Development Stage
Drug Modality Breakdown
Competitive Landscape
5 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 16 trials with date data
Clinical Trials (27)
Total enrollment: 702 patients across 27 trials
Lorlatinib Continuation Study
Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib
A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer
A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China
A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
A Study to Learn About the Study Medicine (Called Lorlatinib) in People With Liver Dysfunction
Effect of Multiple Doses of Modafinil on the Pharmacokinetics of Single Dose Lorlatinib in Healthy Participants
Lorlatinib Renal Impairment Study
A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Single-dose Study of [14C]Lorlatinib (PF-06463922) Metabolism In Healthy Male Volunteers
Olpasiran Expanded Access Program
Individual Patient Expanded Access for AB-SA01, an Investigational Anti-Staphylococcus Aureus Bacteriophage Therapeutic
Lorlatinib - PF-06463922
Individual Patient Expanded Access for AB-PA01, an Investigational Anti-Pseudomonas Aeruginosa Bacteriophage Therapeutic
Expanded Access for Iberdomide
Expanded Access for Anti-IL8
Expanded Access for Bromodomain and Extra-Terminal (BET) Inhibitor
Expanded Access for Relatlimab
Expanded Access for Hereditary Angioedema (HAE)
Expanded Access Use of Ladiratuzumab Vedotin in Advanced Solid Tumors
AMG 701 Expanded Access Program
A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer (NSCLC) Which Has Spread Out.
Study to Evaluate Clinical Real World Outcomes of Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese Patients
Real World Data Collection Pediatric Neuroblastoma Treated With Lorlatinib
A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled